Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this

TCT 2017 Breakfast Symposium

Please mark your calendars to attend the

Keystone Heart Breakfast Symposium at TCT 2017


Progress in Cerebral Embolic Protection

Wednesday, November 1st

Program check-in and breakfast begins at 6:30AM
Program will run from 7:00AM-8:00AM.
Co-chaired by Raj Makkar and Tamim Nazif

Colorado Convention Center Room 501


1. Dr. Pieter Stella – Critical review of neurological effects of invasive cardiac procedures: Do we need to do better?

2. Dr. Alexandra Lansky – The search for meaningful measures of clinical efficacy: NeuroARC and beyond.

3. Dr. Tamim Nazif – Practical considerations and design requirements for clinically relevant CEP: The Keystone TriGUARD 3™ device.

4. Dr. Jeffrey Moses – Building the evidence for CEP in TAVR: Critical review of the clinical trial data and REFLECT update.

5. Flash debate and discussion – moderated by Dr. Raj Makkar 
a. Dr. Richard Smalling – CEP should only be used judiciously in selected TAVR patients.
b. Dr. Samir Kapadia – CEP is necessary and indicated for all TAVR procedures.Investigational Device.

Limited by Federal (or United States) law to investigational use. “TriGUARD” & TriGUARD 3™ are trademarks owned by Keystone Heart, LTD, and may be registered. All other trademarks are the property of their respective owners.  

No Comments

Leave a reply